Top

Published in:

01-02-2017 | Editorial

Multimodality imaging in the diagnosis and management of cardiac sarcoidosis

Authors: Shant J. Manoushagian, MD, Vladimir Lakhter, DO, Pravin V. Patil, MD

Published in: Journal of Nuclear Cardiology | Issue 1/2017

Excerpt

Sarcoidosis is a multisystem disorder that is characterized histologically by non-caseating, non-necrotic granulomas. Although it most commonly manifests in the lungs or with lymphadenopathy, it can affect any organ. Cardiac Sarcoidosis (CS) occurs with an incidence of 5%-39% depending on detection method, and has a wide range of clinical manifestations, from no symptoms to sudden cardiac death.1 CS is considered to be the second leading cause of death by sarcoidosis in the United States,1 making diagnosis and monitoring the progression of disease of utmost importance. …

Schatka I, Bengel FM. Advanced imaging of cardiac sarcoidosis. J Nucl Med. 2014;55(1):99-106.CrossRefPubMed

Hulten E, Aslam S, Osborne M, Abbasi S, Bittencourt MS, Blankstein R. Cardiac sarcoidosis—State of the art review. Cardiovasc Diagn Ther. 2016;6(1):50-63.PubMedPubMedCentral

McArdle BA, Leung E, Ohira H, Cocker MS, deKemp RA, DaSilva J, et al. The role of F¹⁸-fluorodeoxyglucose positron emission tomography in guiding diagnosis and management in patients with known or suspected cardiac sarcoidosis. J Nucl Cardiol. 2013;20:297-306.CrossRef

Sobic-Saranovic D, Artiko V, Obradovic V. FDG pet imaging in sarcoidosis. Semin Nucl Med. 2013;43:404-11.CrossRefPubMed

Youssef G, Leung E, Mylonas I, Nery P, Williams K, Wisenberg G, et al. The use of ¹⁸F-FDG PET in the diagnosis of cardiac sarcoidosis: A systematic review and metaanalysis including the ontario experience. J Nucl Med. 2012;53:241-8.CrossRefPubMed

Blankstein R, Osborne M, Naya M, Waller A, Kim CK, Murthy VL, et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. JACC. 2014;63(4):329-36.CrossRefPubMed

Gormsen LC, Haraldsen A, Kramer S, Dias AH, Kim WY, Borghammer P. A dual tracer ⁶⁸Ga-DOTANOC PET/CT and ¹⁸F-FDG PET/CT pilot study for detection of cardiac sarcoidosis. EJNMMI Res. 2016;6:52-63.CrossRefPubMedPubMedCentral

Manabe O, Hirata K, Shozo O, Shiga T, Uchiyama Y, Kobayashi K, et al. ¹⁸F-fluoromisonidazole (FMISO) PET may have the potential to detect cardiac sarcoidosis. J Nucl Cardiol. 2016. doi:10.1007/s12350-016-0495-2.

Smedema JP, Snoep G, van Kroonenburgh MPG, van Geuns RJ, Dassen WRM, Gorgels APM, et al. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol. 2005;45:1683-90.CrossRefPubMed

10.

Blankstein R, Waller AH. Evaluation of known or suspected cardiac sarcoidosis. Circ Cardiovasc Imaging. 2016;9:e000867.CrossRefPubMed

11.

Patel MR, Cawley PJ, Heitner JF, Klem I, Parker MA, Jaroudi WA, et al. Detection of myocardial damage in patients with sarcoidosis. Circulation. 2009;120:1969-77.CrossRefPubMedPubMedCentral

12.

Murtagh G, Laffin LJ, Beshai JF, Maffessanti F, Bonham CA, Patel AV, et al. Prognosis of myocardial damage in sarcoidosis patients with preserved left ventricular ejection fraction: Risk stratification using cardiovascular magnetic resonance. Circ Cardiovasc Imaging 2016;9(1):e003738.CrossRefPubMedPubMedCentral

13.

Crouser ED, Ono C, Tran T, He X, Raman SV. Improved detection of cardiac sarcoidosis using magnetic resonance with myocardial T2 mapping. Am J Respir Crit Care Med 2014;189:109-12.PubMedPubMedCentral

14.

Orii M, Hirata K, Tanimoto T, Ota S, Shiono Y, Yamano T, et al. Comparison of cardiac MRI and (18)F-FDG positron emission tomography manifestations and regional response to corticosteroid therapy in newly diagnosed cardiac sarcoidosis with complete heart block. Heart Rhythm 2015;12:2477-85.CrossRefPubMed

15.

Crouser ED, Ruden E, Julian MW, Raman SV. Resolution of abnormal cardiac MRI T2 signal following immune suppression for cardiac sarcoidosis. J Investig Med. 2016;64(6):1148-50.CrossRefPubMed

16.

White JA, Rajchl M, Butler J, Thompson RT, Prato FS, Wisenberg G. Active cardiac sarcoidosis—First clinical experience of simultaneous positron emission tomography-magnetic resonance imaging for the diagnosis of cardiac disease. Circulation 2013;127:e639-41.CrossRefPubMed

17.

Lee P, Cheng G, Alavi A. The role of serial FDG PET for assessing therapeutic response in patients with cardiac sarcoidosis. J Nucl Cardiol 2016 (accepted for publication).

18.

Osborne MT, Hulten EA, Singh A, Waller AH, Bittencourt MS, Stewart GC, et al. Reduction in ¹⁸F-fluorodeoxyglucose uptake on serial cardiac positron emission tomography is associated with improved left ventricular ejection fraction in patients with cardiac sarcoidosis. J Nucl Cardiol 2014;21:166-74.CrossRefPubMed

19.

Yamagishi H, Shirai N, Takagi M, Yoshiyama M, Akioka K, Takeuchi K, et al. Identification of cardiac sarcoidosis with ¹³N-NH₃/¹⁸F-FDG PET. J Nucl Med 2003;44:1030-6.PubMed

20.

Matoh F, Satoh H, Shiraki K, Odagiri K, Saitoh T, Urushida T, et al. The usefulness of delayed enhancement magnetic resonance imaging for diagnosis and evaluation of cardiac function in patients with cardiac sarcoidosis. J Cardiol 2008;51:179-88.CrossRefPubMed

21.

Vignaux O, Dhote R, Duboc D, Blanche P, Dusser D, Weber S, et al. Clinical significance of myocardial magnetic resonance abnormalities in patients with sarcoidosis: A 1-year follow-up study. Chest 2002;122:1895-901.CrossRefPubMed

Title: Multimodality imaging in the diagnosis and management of cardiac sarcoidosis
Authors: Shant J. Manoushagian, MD
Vladimir Lakhter, DO
Pravin V. Patil, MD
Publication date: 01-02-2017
Publisher: Springer US
Published in: Journal of Nuclear Cardiology / Issue 1/2017
Print ISSN: 1071-3581
Electronic ISSN: 1532-6551
DOI: https://doi.org/10.1007/s12350-016-0721-y

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

At a glance: The STEP trials

Springer Medicine

Multimodality imaging in the diagnosis and management of cardiac sarcoidosis

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2017

A Shot to the Heart

Anomalous coronary arteries: What we know and what we do not know

A quick glance at selected topics in this issue

Prognostic impact of SPECT-MPI after renal transplantation

Myocardial 123I-metaiodobenzylguanidine scintigraphy in patients with homozygous and heterozygous parkin mutations

Challenges of cardiac inflammation imaging with F-18 FDG positron emission tomography

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page